ANIP ANI Pharmaceuticals
- 62.455
- -1.315-2.06%
ANI Pharmaceuticals News
Insider Selling: President & CEO Nikhil Lalwani Sells Shares of ANI Pharmaceuticals Inc (ANIP)
ANI Pharmaceuticals(ANIP.US) Officer Sells US$1.1 Million in Common Stock
$ANI Pharmaceuticals(ANIP.US)$ Officer Lalwani Nikhil sold 16,669 shares of common stock on May 14, 2024 at an average price of $66.1 for a total value of $1.1 million.Source: Announcement What is sta
Ani Pharmaceuticals Insider Sold Shares Worth $1,101,821, According to a Recent SEC Filing
Nikhil Lalwani, Director, President & CEO, on May 14, 2024, sold 16,669 shares in Ani Pharmaceuticals (ANIP) for $1,101,821. Following the Form 4 filing with the SEC, Lalwani has control over a total
Form 144 | ANI Pharmaceuticals(ANIP.US) Insider Proposes to Sell 127.73K in Common Stocks
SEC FILLINGS DISCLOSED/ May 16, $ANI Pharmaceuticals(ANIP.US)$ Insider RENATE TANNENBAUM intends to sell 2,000 shares of its common stock on May 16, with a total market value of approximately $127.73K
Form 144 | ANI Pharmaceuticals(ANIP.US) Officer Proposes to Sell 1.05 Million in Common Stocks
SEC FILLINGS DISCLOSED/ May 16, $ANI Pharmaceuticals(ANIP.US)$ Officer Shanmugam Muthusamy intends to sell 16,459 shares of its common stock on May 16, with a total market value of approximately $1.05
Form 144 | ANI Pharmaceuticals(ANIP.US) Officer Proposes to Sell 978K in Common Stocks
SEC FILLINGS DISCLOSED/ May 15, $ANI Pharmaceuticals(ANIP.US)$ Officer Shanmugam Muthusamy intends to sell 14,850 shares of its common stock on May 15, with a total market value of approximately $978K
Form 144 | ANI Pharmaceuticals(ANIP.US) Officer Proposes to Sell 1.1 Million in Common Stocks
SEC FILLINGS DISCLOSED/ May 14, $ANI Pharmaceuticals(ANIP.US)$ Officer Lalwani Nikhil intends to sell 16,669 shares of its common stock on May 14, with a total market value of approximately $1.1 milli
ANI Pharmaceuticals Financial Health Overview Released
ANI Pharmaceuticals(ANIP.US) Officer Sells US$16,922.5 in Common Stock
$ANI Pharmaceuticals(ANIP.US)$ Officer Cook Meredith sold 250 shares of common stock on May 13, 2024 at an average price of $67.69 for a total value of $16,922.5.Source: Announcement What is statement
ANI Pharmaceuticals Price Target Raised to $87.00/Share From $83.00 by HC Wainwright & Co.
ANI Pharmaceuticals Price Target Raised to $87.00/Share From $83.00 by HC Wainwright & Co.
ANI Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
ANI Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on ANI Pharmaceuticals, Raises Price Target to $87
HC Wainwright & Co. analyst Oren Livnat maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and raises the price target from $83 to $87.
ANI Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 27.85% HC Wainwright & Co. $83 → $87 Maintains Buy 04/23/2024 13.15% Guggenheim → $77 Reiterate
Is ANI Pharmaceuticals (NASDAQ:ANIP) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), ANI Pharmaceuticals (ANIP) and Argenx Se (ARGX)
ANI Pharmaceuticals Inc (ANIP) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and ...
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q1 2024 Earnings Call Transcript
Earnings Call Summary | ANI Pharmaceuticals(ANIP.US) Q1 2024 Earnings Conference
The following is a summary of the ANI Pharmaceuticals, Inc. (ANIP) Q1 2024 Earnings Call Transcript:Financial Performance:ANI Pharmaceuticals reported Q1 revenues of $137.4 million, showing a 29% incr
ANI Pharmaceuticals Reports Strong Q1 2024 Results, Surpassing Revenue Expectations
ANI Pharmaceuticals Q1 Adjusted Earnings, Revenue Rise; Reaffirms Full Year 2024 Earnings, Revenue Guidance
ANI Pharmaceuticals (ANIP) reported Q1 earnings Friday of $1.21 per diluted share, up from $1.17 a year earlier.
Analysis
Price Target
No Data
